Normal 0 false false false MicrosoftInternetExplorer4 Rosetta Genomics (NASDAQ: ROSG) shares hiked 21.3% to $4.84 after the leading developer and provider of microRNA-based molecular diagnostic assays announced that the New York State Department of Health has given the Company final approval for its miRview® lung assay following conditional approval issued last June. Share volume was 269,000 compared to a daily average of 391,000. /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman"; mso-ansi-language:#0400; mso-fareast-language:#0400; mso-bidi-language:#0400;}